IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1001-1025 out of 1243.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

Public Release: 27-May-2014
Cell Reports
New jigsaw piece for the repair of DNA crosslinks
DNA damage repair is highly complex. UZH researchers have now discovered another piece in the puzzle for the removal of extremely dangerous DNA lesions. Faithful and efficient repair of so-called crosslinks requires a collaboration between a specific signalling and repair protein. As crosslink-inducing agents are used in chemotherapy, the new insights are also important for the development of better anti-cancer treatment strategies.

Contact: Dr. Alessandro A. Sartori
University of Zurich

Public Release: 27-May-2014
Annals of Allergy, Asthma & Immunology
E-cigarettes: Not a healthy alternative to smoking
A new study examines the risks of e-cigarettes.

Contact: Hollis Heavenrich-Jones
American College of Allergy, Asthma, and Immunology

Public Release: 27-May-2014
An area's level of poverty or wealth may affect the distribution of cancer types
A new analysis has found that certain cancers are more concentrated in areas with high poverty, while other cancers arise more often in wealthy regions.

Contact: Evelyn Martinez

Public Release: 27-May-2014
Cancer, bioelectrical signals and the microbiome connected
Bioelectrical signals from distant cells control the incidence of tumors arising from cancer-causing genes in tadpoles, and this process is impacted by levels of a common fatty acid produced by bacteria in the tadpole and also in humans. This research has important implications for preventing, diagnosing and treating cancer, and for understanding the role of genetics and physiology in oncology.
G. Harold and Leila Y. Mathers Charitable Foundation, Defense Advanced Research Projects Agency

Contact: Kim Thurler
Tufts University

Public Release: 27-May-2014
Proceedings of the National Academy of Sciences
Two new possible drug targets for triple negative breast cancer
The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment, report scientists in the Proceedings of the National Academy of Sciences. The findings may help medical researchers identify effective drug targets for triple negative breast cancer, or TNBC.
National Institutes of Health, Golfers Against Cancer, Breast Cancer Research Foundation

Contact: David Bricker
Houston Methodist

Public Release: 27-May-2014
EMBO Molecular Medicine
Researchers identify a new suppressor of breast metastasis to the lung
The research headed by Roger Gomis at IRB Barcelona, with the collaboration of Joan Massagué, describes that the loss of the suppressor RARRES3 promotes the colonization of breast cancer cells in the lung. RARRES3 could prove to be a useful marker to identify patients with a greater risk of metastasis, as well as providing a target for the development of a specific treatment for preventive strategies after removal of the primary tumor.
BBVA Foundation, Asociación Española Contra el Cáncer, Generalitat de Catalunya, gobierno de España

Contact: Sònia Armengou
Institute for Research in Biomedicine (IRB Barcelona)

Public Release: 27-May-2014
Medical Care
More access to health care may lead to unnecessary mammograms
Researchers have concluded that providing better access to health care may lead to the overuse of mammograms for women who regularly see a primary care physician and who have a limited life expectancy. The cautionary note from researchers at the University of Texas Medical Branch at Galveston is that screening women in this category could subject them 'to greater risks of physical, emotional and economic suffering.'
Cancer Prevention Research Institute of Texas, National Institutes of Health

Contact: Raul Reyes
University of Texas Medical Branch at Galveston

Public Release: 27-May-2014
Developmental Cell
UCI researchers identify new functional roles on cell surfaces for estrogen
A discovery by UC Irvine endocrinologists about the importance of cell surface receptors for estrogen has the potential to change how researchers view the hormone's role in normal organ development and function.
National Institutes of Health, Department of Veterans Affairs

Contact: Tom Vasich
University of California - Irvine

Public Release: 27-May-2014
New University of Colorado study illuminates how cancer-killing gene may actually work
Scientists armed with a supercomputer and a vast trove of newly collected data on the body's most potent "tumor suppressor" gene have created the best map yet of how the gene works, an accomplishment that could lead to new techniques for fighting cancers, which are adept at disabling the gene in order to thrive.
Howard Hughes Medical Institute, National Institutes of Health, National Science Foundation

Contact: Garth Sundem
University of Colorado Denver

Public Release: 27-May-2014
Journal of Clinical Oncology
Study identifies risk of chemotherapy related hospitalization for eary-stage breast cancer patients
Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center.

Contact: Laura Sussman
University of Texas M. D. Anderson Cancer Center

Public Release: 26-May-2014
Breast Cancer Research and Treatment
Fighting cancer with dietary changes
Calorie restriction during treatment for breast cancer changes cellular programming in a way that lowers the chance of metastases in mice.

Contact: Edyta Zielinska
Thomas Jefferson University

Public Release: 26-May-2014
Annals of Internal Medicine
Annals of Internal Medicine tip sheet for May 27, 2014
The May 27, 2014, issue of Annals of Internal Medicine covers articles titled: 'Task Force: Screen high-risk individuals for hepatitis B'; 'Postnatal immunoprophylaxis effective for preventing maternal transmission of hepatitis B'; 'Some transitional care interventions more effective than others for reducing mortality, readmissions after heart failure'; and 'Analysis shows cancer center ads heavy on emotion, light on information.'

Contact: Megan Hanks
American College of Physicians

Public Release: 26-May-2014
A novel disease-preventing antioxidant pathway
A team in Singapore has recently showed that uric acid is a major intracellular antioxidant, possibly even more important than the antioxidants we try to eat. They also discovered how uric acid helps to prevent aging and disease and how it helps in the treatment of cancer.
Singapore Ministry of Education

Contact: Dharshini Subbiah
Duke-NUS Graduate Medical School Singapore

Public Release: 25-May-2014
Nature Chemical Biology
Team validates potentially powerful new way to treat HER2-positive breast cancer
Scientists at Cold Spring Harbor Laboratory today reported a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer called HER2-positive.
National Institutes of Health, American Diabetes Association, Brown University Seed Fund Cold Spring Harbor Laboratory Cancer Center

Contact: Peter Tarr
Cold Spring Harbor Laboratory

Public Release: 25-May-2014
Nature Medicine
Gene mutation found for aggressive form of pancreatic cancer
Researchers at the University of California, San Diego School of Medicine have identified a mutated gene common to adenosquamous carcinoma tumors -- the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer.
National Key Basic Research Program of China, National Natural Science Foundation of China

Contact: Scott LaFee
University of California - San Diego

Public Release: 25-May-2014
Nature Medicine
Scientists discover potential new target for cancer immunotherapy
Myeloid-derived suppressor cells are found abundantly in the microenvironment around tumors. They suppress immune response and promote cancer progression. They've been hard to target, but MD Anderson researchers have identified a potential route of attack.
NIH/National Cancer Institute

Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Public Release: 25-May-2014
Nature Cell Biology
Study identifies how signals trigger cancer cells to spread
Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a signaling pathway in cancer cells that controls their ability to invade nearby tissues in a finely orchestrated manner. The findings offer insights into the early molecular events involved in metastasis, the deadly spread of cancer cells from primary tumor to other parts of the body. The study was published today in the online edition of Nature Cell Biology.
National Institutes of Health

Contact: Kim Newman
Albert Einstein College of Medicine

Public Release: 23-May-2014
ASCO 50th Annual Meeting
Yale Cancer Center's tip sheet for the 50th Annual Meeting of ASCO May 30-June 3, 2014
The news items below are from oral presentations or poster sessions scheduled for the 50th annual ASCO conference. Yale Cancer Center will have experts available to speak with the media before or during ASCO. Abstracts cover immunotherapy for Melanoma and Bladder Cancer; PSMA; Breast Cancer Biomarkers; Cervical Cancer Screening; Non-Small Cell Lung Cancer; and Mental Health Comorbidities in VA Patients.

Contact: Vicky Agnew
Yale University

Public Release: 23-May-2014
Scientific Reports
New sensor could light the way forward in low-cost medical imaging
New research published today in Nature's Scientific Reports, identifies a new type of light sensor that could allow medical and security imaging, via low cost cameras.

Contact: Amy Sutton
University of Surrey

Public Release: 23-May-2014
Wound-healing role for microRNAs in colon offer new insight to inflammatory bowel diseases
A microRNA cluster believed to be important for suppressing colon cancer has been found to play a critical role in wound healing in the intestine, UT Southwestern cancer researchers have found.

Contact: Russell Rian
UT Southwestern Medical Center

Public Release: 23-May-2014
New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated in a phase I study.
Millennium: The Takeda Oncology Company

Contact: David Bricker
Houston Methodist

Public Release: 22-May-2014
Yale Cancer Center studies find lifestyle changes improve biomarkers for breast cancer recurrence and mortality
A pair of Yale Cancer Center interventional studies involving breast cancer survivors found that lifestyle changes in the form of healthy eating and regular exercise can decrease biomarkers related to breast cancer recurrence and mortality. The abstracts are scheduled to be presented at the 2014 annual meeting of the American Society of Clinical Oncology in Chicago May 30-June 3rd.

Contact: Vicky Agnew
Yale University

Public Release: 22-May-2014
Cell Reports
Researchers identify key mechanism in metabolic pathway that fuels cancers
A UT Southwestern research team has taken a significant step in cracking the code of an atypical metabolic pathway that allows certain cancerous tumors to thrive, providing a possible roadmap for defeating such cancers.

Contact: Mark Lane
UT Southwestern Medical Center

Public Release: 22-May-2014
Proceedings of the National Academy of Sciences
Signals found that recruit host animals' cells, enabling breast cancer metastasis
Working with mice, Johns Hopkins researchers report they have identified chemical signals that certain breast cancers use to recruit two types of normal cells needed for the cancers' spread. A description of the findings appears in the online early May edition of the Proceedings of the National Academy of Sciences.
American Cancer Society, NIH/National Cancer Institute

Contact: Shawna Williams
Johns Hopkins Medicine

Public Release: 22-May-2014
Clinical trials designed to block autophagy in multiple cancers show promise
In the largest group of results to date, researchers from Penn Medicine's Abramson Cancer Center and other institutions have shown in clinical trials that the malaria drug hydroxychloroquine blocked autophagy in a host of aggressive cancers -- glioblastoma, melanoma, lymphoma and myeloma, renal and colon cancers -- and in some cases helped stabilize disease.

Contact: Steve Graff
University of Pennsylvania School of Medicine

Showing releases 1001-1025 out of 1243.

<< < 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 > >>

  Search News Releases